Authors
Latest:
Dr. Palmerini on Long-term Efficacy of Denosumab in Giant Cell Tumor of BoneEmanuela Palmerini, MD, Prometeo Laboratory: Clinical and Experimental Research Contract, Chemotherapy for Rare Musculoskeletal Tumors Department, Rizzoli Orthopaedic Institute, discusses the long-term efficacy of denosumab (Xgeva) in patients with giant cell tumor of bone.
Latest:
Dr. Zsiros Discusses Pembrolizumab Triplet in Recurrent Ovarian CancerEmese Zsiros, MD, PhD, discusses the results of her recent phase II trial that set out to evaluate the use of pembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide in the treatment of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Latest:
Dr. Rutgers Compares ART or ALND in Breast CancerEmiel J. Rutgers, MD, surgical oncologist, Netherlands Cancer Institute, Amsterdam, discusses a study analyzing radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer patients.
Latest:
Dr. Cohen on Eligibility for Ablation Therapy in Liver CancerEmil Israel Cohen, MD, an assistant professor at Medstar Georgetown University Hospital, discusses the criteria for ablation therapy in patients with liver cancer.
Latest:
Best Initial Treatment Strategies for EGFR-Mutant Lung CancerThis review will focus on current therapies used in the first-line setting for advanced EGFR mutation positive non–small cell lung cancer (NSCLC) followed by emerging data that may lead to a transition in the choice for initial therapy in these patients.
Latest:
From "Least Engaged" to "Most Happy": 4 Types of OCM ParticipantThe goal of the Oncology Care Model is to incentivize high-quality, coordinated care with an episode-based payment model that emphasizes patient access and navigation.
Latest:
Dr. Chan Discusses the VEGF-Trap Agent AfliberceptDr. Emily Chan, from Vanderbilt-Ingram Cancer Center, Discusses the VEGF-Trap Agent Aflibercept
Latest:
Dr. Ko on Surgery as an Effective Option for Patients With Endometrial CancerEmily Ko, MD, assistant professor of Obstetrics and Gynecology, University of Pennsylvania Health System, discusses why surgery is an effective option for patients with endometrial cancer.
Latest:
Dr Barber on the Significance of the KEYNOTE-775 Trial for the Second-line Treatment of Endometrial CancerEmma L. Barber, MD, discusses how key data from the phase 3 KEYNOTE-775 study improved the identification of patient populations within endometrial cancer that benefit from second-line immunotherapy.
Latest:
Novel Agents Revolutionize Melanoma TreatmentUntil recently, the cornerstone of therapy for metastatic melanoma had been chemotherapy with dacarbazine (DTIC) and immunotherapy with high-dose interleukin-2 (HD IL-2) or interferon-α (IFN-α).
Latest:
Rituximab for Chronic Lymphocytic Leukemia in Treatment-Naïve and Treatment-Experienced PatientsA mixed treatment comparison demonstrated that FCR significantly prolonged PFS compared with all other treatments and significantly increased ORR compared with all other treatments.
Latest:
Dr. Antonarakis on Trial Examining Sipuleucel-T Plus Radium-223 in Bone-Metastatic CRPCEmmanuel S. Antonarakis, MBBCh, discusses the design of a randomized phase II study of sipuleucel-T with or without radium-223 dichloride in men with asymptomatic bone-metastatic castrate-resistant prostate cancer.
Latest:
Drs Antonarakis and Jha on Extending Clinical Trials to the Community SettingEmmanuel Antonarakis, MD, and Gautam Jha, MD, on collaboration efforts extending the reach of clinical trials beyond university hospitals.
Latest:
Dr. Tiacci on Vemurafenib and Rituximab Combo in Hairy Cell LeukemiaEnrico Tiacci, MD, discusses updated data of a phase II trial investigating the combination of vemurafenib and rituximab for patients with relapsed/refractory hairy cell leukemia.
Latest:
Dr. Grande on the Rationale of the IMvigor130 Trial in Urothelial CancerEnrique Grande, MD, discusses the rationale of the IMvigor130 trial in urothelial cancer.
Latest:
Dr. Soto Perez de Celis on COVID-19 Risk ReductionEnrique Soto Pérez de Celis, MD, MSc, a geriatric oncologist and researcher in the Department of Geriatrics at the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán in Mexico City, Mexico, discusses ways to reduce the risk of contracting the novel coronavirus 2019 (COVID-19).
Latest:
Dr. Felip on Immunotherapy Alone or in Combination in Lung CancerEnriqueta Felip, MD, discusses immunotherapy alone versus immunotherapy plus chemotherapy in patients with lung cancer.
Latest:
Dr. Felip Discusses Ceritinib's Response in ALK+ NSCLCEnriqueta Felip, MD, PhD, medical oncologist, Vall d'Hebron University Hospital, Barcelona, Spain, discusses the efficacy and safety of ceritinib in patients with ALK-positive non-small cell lung cancer (NSCLC).
Latest:
Cost-Effectiveness of 70-Gene MammaPrint Signature in Node-Negative Breast CancerBreast cancers with similar clinicopathologic characteristics may have strikingly different outcomes.
Latest:
Dr. Collisson on the Difficulty of Diagnosing CholangiocarcinomaEric A. Collisson, MD, associate professor, Department of Medicine, University of California, San Francisco Helen Diller Comprehensive Cancer Center, discusses the difficulty of diagnosing cholangiocarinoma.
Latest:
Relapsed/Refractory Clear Cell RCC: Novel Treatment StrategiesSwitching their focus to relapsed/refractory advanced clear cell renal cell carcinoma, key opinion leaders review treatment options in this setting.
Latest:
Dr. Klein on the Safety of VERU-111 in mCRPCEric Klein, MD, discusses safety data with VERU-111 from a phase 2 trial that enrolled patients with metastatic castration-resistant prostate cancer that was presented during the 2021 Genitourinary Cancers Symposium.
Latest:
Kentucky Taps Into Data Repositories for an Attack on its Extraordinary Cancer BurdenOpen access to unbiased data repositories of molecular and clinical data will be essential to accelerating future discoveries in precision medicine.
Latest:
Dr. Eric Haura on New Biomarker Assay System for Lung CancerEric Haura, MD, senior member, Moffitt Cancer Center, discusses new approaches to identifying bypass signaling mechanisms and biomarkers in lung cancer.
Latest:
Association Between BMI and Pancreatic Cancer MortalityEric J. Jacobs, PhD, cancer epidemiologist and strategic director of pharmacoepidemiology, American Cancer Society, discusses results from a prospective cohort study examining the association between BMI and pancreatic cancer mortality.
Latest:
Dr. Sherman on Selumetinib-Enhanced Radioiodine UptakeEric J. Sherman, MD, Head and Neck Oncology Service, Memorial Sloan-Kettering Cancer Center, discusses a pilot study of selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.
